In addition to marketing authorisation, Fimea provides many other permits and certificates relating to medicinal products.
A product with marketing authorisation can be granted an exemption if the product is critical for pharmaceutical services in Finland and its availability would be interrupted otherwise.
Read more: Exemptions
Special permissions for compassionate use
Special permissions can be granted for special medicinal reasons to products that do not have marketing authorisation in Finland.
Read more: Special permissions
Fimea grants batch-specific permits for releasing plasma-based medicinal products, immunoserums and vaccines used for immunoprophylaxis on the market.
Read more: Batch-specific control
Certificate of a pharmaceutical product (CPP)
Fimea provides pharmaceutical plants with certificates of a pharmaceutical product (CPP) for export purposes.
Read more: Certificates of a pharmaceutical product
By application from the marketing authorisation holder, Fimea may grant a permit for a package size intended for dose-dispensing for a product with marketing authorisation.
Read more: Dose-dispensing
Authorisation of clinical drug trials
Fimea also processes authorisation applications for clinical drug trials.
Read more: Clinical drug trials